Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center

Table 3 Uni- and multi-variate analysis of survival in patients with thymic malignancies

Univariate analysis
Variants	Thymoma			Thymic carcinoma
	n	MST [95% CI]	p-value	n	MST [95% CI]	p-value
Age (y)			0.0018*			0.36
<70	91	71.3 [54.4-88.1]		50	24.1 [13.5-43.6]
≥70	28	30.1 [13.8-59.9]		18	24.6 [11.9-36.4]
Gender			0.29			0.076
Male	52	235.2 [136.8-NR]		38	29.7 [13.5-40.2]
Female	67	171.8 [110.1- NR]		30	56.4 [23.7-73.0]
Masaoka-Koga Stage			0.0012*			0.18
I	52	NR [136.8- NR]		0	-
II	31	NR [NR - NR]		6	78.9 [65.8-92.0]
III	12	171.8 [4.7- NR]		10	56.4 [8.8-99.6]
IVa	18	110.1 [33.8-235.2]		16	27.3 [17.2-43.9]
IVb	6	83.8 [0.6- NR]		36	21.6 [11.3-36.4]
Immunological abnormalities			0.26			0.59
Yes	26	NR [171.8- NR]		2	71.2 [69.5-73.0]
No	93	156.6 [126.3- NR]		66	30.4 [23.6-43.9]
Secondary Malignancies			0.42			0.54
Yes	12	235.2 [74.4-235.2]		13	36.8 [5.8-65.8]
No	107	171.8 [136.8- NR]		55	30.4 [21.6-56.4]
WHO classification [thymoma]			0.68
A	5	79.2 [-]
AB	33	- [91.6- NR]
B1	19	- [126.3- NR]
B2	39	171.8 [110.1- NR]
B3	15	- [37.2- NR]
Other	8	235.2 [4.4-235.2]
[thymic carcinoma]						0.95
High grade				52	36.8 [23.7-65.8]
Low grade				16	24.7 [8.5-66.6]
Multivariate analysis
Variants	Thymoma			Thymic carcinoma
	HR	95% CI	P-value	HR	95% CI	p-value
Staging	IVa/ I: 4.62	[1.78-13.37]	0.016*	II/IVa: 0.27	[0.43-0.99]	0.048*
	IVa/II: 6.40	[2.03-28.17]	0.001*
	IVb/II: 5.56	[1.02-30.20]	0.047*
Immunological abnormalities	2.0	[0.73-6.35]	0.18
Secondary Malignancies	4.4	[0.63-51.9]	0.26	1.36	[0.57-3.28]	0.44
WHO Classification
(A/B1/B2/B3/AB/other)	none	none	none	-	-	-
(high grade vs. low grade)	-	-	-	0.88	[0.46-1.57]	0.70
(thymic ca. vs. thymoma)	6.7	4.1-11.1	< .0001*	-	-	-

NR, not reached; CI, confidence interval; MST, median survival time; HR, hazard ratio; CI confidence interval; *p < 0.05.

ISSN: 1471-2407